In one cohort, anti-CTLA-4 increased expression of PD-1 and VISTA inhibitory checkpoints in prostate tumors, which makes targeting CTLA-4, PD-1, and VISTA an appealing combinatorial approach (158). Here, VSIR is linked to prostate neoplasm.